152 related articles for article (PubMed ID: 24346678)
41. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
42. [Efficacy of two nucleoside analogs to treat resistant HBeAg-negative chronic hepatitis B].
Li XJ; Zhu JY; Shu X; Xu QH
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Aug; 25(4):295-7. PubMed ID: 22097612
[TBL] [Abstract][Full Text] [Related]
43. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
[TBL] [Abstract][Full Text] [Related]
44. Chronic hepatitis B--treatment with nucleoside analogues.
Leung N
Med J Malaysia; 2005 Jul; 60 Suppl B():22-7. PubMed ID: 16108169
[TBL] [Abstract][Full Text] [Related]
45. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L;
N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138
[TBL] [Abstract][Full Text] [Related]
46. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy.
Liang Y; Jiang J; Su M; Liu Z; Guo W; Huang X; Xie R; Ge S; Hu J; Jiang Z; Zhu M; Wong VW; Chan HL
Aliment Pharmacol Ther; 2011 Aug; 34(3):344-52. PubMed ID: 21671967
[TBL] [Abstract][Full Text] [Related]
47. Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues.
Papatheodoridis GV
Liver Int; 2011 Jan; 31 Suppl 1():95-103. PubMed ID: 21205145
[TBL] [Abstract][Full Text] [Related]
48. Analogs and fibrosis regression in hepatitis B.
Bourlière M; Kahloun A; Gascou-Tessonnier G
Gastroenterol Clin Biol; 2009; 33(10-11):923-9. PubMed ID: 19640665
[TBL] [Abstract][Full Text] [Related]
49. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
[TBL] [Abstract][Full Text] [Related]
50. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H
Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607
[TBL] [Abstract][Full Text] [Related]
51. Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir.
Wang JC; He LL; Chen Q
Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1162-6. PubMed ID: 23690184
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
Liaw YF; Raptopoulou-Gigi M; Cheinquer H; Sarin SK; Tanwandee T; Leung N; Peng CY; Myers RP; Brown RS; Jeffers L; Tsai N; Bialkowska J; Tang S; Beebe S; Cooney E
Hepatology; 2011 Jul; 54(1):91-100. PubMed ID: 21503940
[TBL] [Abstract][Full Text] [Related]
53. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments.
Yap DY; Tang CS; Yung S; Choy BY; Yuen MF; Chan TM
Transplantation; 2010 Aug; 90(3):325-30. PubMed ID: 20562676
[TBL] [Abstract][Full Text] [Related]
54. [Comparison of the efficacy of 48 week-Entecavir therapy with that of Adefovir therapy for chronic hepatitis B patients].
Lin Q; Zhang DZ; Zhou Z; Hu P; Wang ZY; Shi XF; Zeng WQ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2010 May; 18(5):338-41. PubMed ID: 20509997
[TBL] [Abstract][Full Text] [Related]
55. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
[TBL] [Abstract][Full Text] [Related]
56. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G
Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449
[TBL] [Abstract][Full Text] [Related]
57. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
[TBL] [Abstract][Full Text] [Related]
58. Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
Leung N
Liver Int; 2011 Jan; 31 Suppl 1():85-9. PubMed ID: 21205143
[TBL] [Abstract][Full Text] [Related]
59. Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection.
Gornals JB; Casanovas T; Sabidó M; Baliellas C; Casanovas A; Cañas C; Serrano T; Verdura B; Chahri N; Gil-Vernet S; Figueras J
Transplant Proc; 2005 Nov; 37(9):3957-9. PubMed ID: 16386595
[TBL] [Abstract][Full Text] [Related]
60. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
Sherman M; Yurdaydin C; Simsek H; Silva M; Liaw YF; Rustgi VK; Sette H; Tsai N; Tenney DJ; Vaughan J; Kreter B; Hindes R;
Hepatology; 2008 Jul; 48(1):99-108. PubMed ID: 18537189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
